J&J’s Discontinuation Of Johnson’s Baby Powder Linked To April Federal Court Ruling
Executive Summary
Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.
You may also be interested in...
In Talc Litigation On ‘Baseless Scientific Claims,’ J&J Says Settlement Offers Plaintiffs 'Certainty’
Firm reiterates stance on safety of talc as it reports 7.4% Q1 growth in consumer health product sales contributes to earnings guidance boost. It reports $3.85bn consumer health sales with US sales up 11.4% to $1.74bn and international sales 4.4% to $2.12bn.
J&J’s Rumored Plan To End Talc Litigation Through Bankruptcy ‘Contemptible’ – Plaintiffs’ Attorneys
Plaintiffs’ attorneys blast J&J for reportedly considering weaseling out of its fiscal responsibilities by reorganizing its business away from talc liabilities, which could draw out tort proceedings and significantly reduce plaintiff awards, they suggest.
J&J Appeal Of $2bn Talcum Powder Judgment Denied By US Supreme Court
The Supreme Court said on 1 June that it would not review a $2bn verdict in Missouri for 22 women who alleged links between ovarian cancer and asbestos-tainted talc in Johnson’s Baby Powder. J&J believes the US' top court passed on an "extraordinary opportunity" that "leaves unresolved significant legal questions that state and federal courts will continue to face."